Ark Therapeutics Group plc (‘Ark’) announces today the award of a European Commission grant of Euro2.5m to fund a consortium of commercial and academic collaborators led by Ark to conduct research into advancing the use of insect derived viruses known as baculoviruses (BVs) as vectors for gene-based medicines. Ark will administer and lead the research project, providing key gene-based technologies and expertise from London and Finland whilst collaborating with researchers in Germany, France, The Netherlands and Portugal.
